BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

H1N1 influenza vaccine: Phase I started

Not-for-profit Fraunhofer USA Center for Molecular Biotechnology (Newark, Del.) began a single-blind, placebo-controlled, dose-escalation, U.S. Phase I trial in 80 healthy volunteers to evaluate 2 intramuscular doses of 15, 45 and 90 µg H1N1 influenza vaccine with or without an alum...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >